chartexchange

ATHE
Alterity Therapeutics Limited
stockNASDAQADR

At CloseNov 17, 2026 3:54:07 PM EST
1.90USD-3.061%(-0.06)69,188
1.5700Bid1.9700Ask0.4000Spread
Loading…
Loading…
Healthcare
Biotechnology
HQ
Melbourne, VIC, Australia
Previous Close
$1.96
Beta
1.18
52-Week High
$5.89 2026-07-06
52-Week Low
$1.70 2026-11-13
SMA 50
$2.99
SMA 200
$3.92
Avg. Vol 10D
446,272
Avg. Vol 30D
166,271
Avg. Vol 90D
66,241
Relative Vol
0.42
11.61M
1.5400%
5,001
Jan 9, 2023 · 1-for-10 (reverse)
ATHE Profile

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.

ATHE Performance
PeriodPriceDateChangeBeta
1W2.322026-11-10-19.83%-0.045
1M2.622026-10-16-29.01%1.682
3M4.572026-08-17-59.30%1.431
6M4.342026-05-18-57.09%0.945
1Y3.792025-11-17-50.98%1.180
2Y1.102024-11-18+69.86%—
5Y11.102021-11-17-83.24%0.165
ATHE Stock Summary

Alterity Therapeutics Limited (NASDAQ:ATHE) stock price today is $1.86, and today's volume is 69,136. ATHE is down 5.102% today. The 30 day average volume is 166,271. ATHE market cap is $35.51M with 19.09M shares outstanding.